- Home
- IART vs GRDN Comparison
IART vs GRDN Comparison
Compare IART & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IART
- GRDN
- Stock Information
- Founded
- IART 1989
- GRDN 2004
- Country
- IART United States
- GRDN United States
- Employees
- IART N/A
- GRDN N/A
- Industry
- IART Medical/Dental Instruments
- GRDN Retail-Drug Stores and Proprietary Stores
- Sector
- IART Health Care
- GRDN Consumer Staples
- Exchange
- IART Nasdaq
- GRDN Nasdaq
- Market Cap
- IART N/A
- GRDN 1.6B
- IPO Year
- IART 1995
- GRDN 2024
- Fundamental
- Price
- IART $12.15
- GRDN $21.35
- Analyst Decision
- IART Hold
- GRDN Strong Buy
- Analyst Count
- IART 9
- GRDN 2
- Target Price
- IART $19.43
- GRDN $24.50
- AVG Volume (30 Days)
- IART 1.4M
- GRDN 313.1K
- Earning Date
- IART 07-28-2025
- GRDN 08-15-2025
- Dividend Yield
- IART N/A
- GRDN N/A
- EPS Growth
- IART N/A
- GRDN N/A
- EPS
- IART N/A
- GRDN N/A
- Revenue
- IART $1,624,308,000.00
- GRDN $1,282,307,000.00
- Revenue This Year
- IART $5.56
- GRDN $12.01
- Revenue Next Year
- IART $4.41
- GRDN $2.33
- P/E Ratio
- IART N/A
- GRDN N/A
- Revenue Growth
- IART 6.19
- GRDN 19.55
- 52 Week Low
- IART $11.06
- GRDN $14.16
- 52 Week High
- IART $32.66
- GRDN $26.91
- Technical
- Relative Strength Index (RSI)
- IART 42.29
- GRDN N/A
- Support Level
- IART $11.62
- GRDN N/A
- Resistance Level
- IART $12.07
- GRDN N/A
- Average True Range (ATR)
- IART 0.60
- GRDN 0.00
- MACD
- IART 0.03
- GRDN 0.00
- Stochastic Oscillator
- IART 34.33
- GRDN 0.00
About GRDN Guardian Pharmacy Services Inc. Class A Common Stock
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.